Inactive Instrument

Oncorus, Inc.

Equities

ONCR

US68236R1032

Biotechnology & Medical Research

Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 22, 2023 at 04:26 pm

Oncorus, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 30.9 million compared to USD 17.78 million a year ago. Basic loss per share from continuing operations was USD 1.18 compared to USD 0.69 a year ago.

Latest news about Oncorus, Inc.

North American Morning Briefing : Fed Seen Holding Rates, Powell Comments Key	23-09-20	DJ
North American Morning Briefing : Inflation -2-	23-09-06	DJ
North American Morning Briefing : Stock Futures -2-	23-08-30	DJ
North American Morning Briefing : Nvidia Results -2-	23-08-23	DJ
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
North American Morning Briefing : Traders Absorb -2-	23-08-09	DJ
Oncorus, Inc. Announces Executive Changes	23-08-03	CI
Oncorus, Inc. Announces Changes to Its Board	23-08-03	CI
Oncorus, Inc. Announces Executive Changes	23-08-03	CI
Oncorus, Inc. Announces Board Changes	23-07-28	CI
Oncorus, Inc. Announces Resignation of Douglas M. Fambrough III from its Board of Directors as Well as Compensation Committee, Effective July 20, 2023	23-07-19	CI
Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	23-07-19	CI
Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index	23-06-23	CI
Oncorus, Inc.(OTCPK:ONCR) dropped from NASDAQ Composite Index	23-06-20	CI
Oncorus Announces Management Changes	23-06-07	CI
Oncorus Appoints Brian Shea as Interim Chief Executive Officer	23-06-07	CI
Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-06-02	MT
North American Morning Briefing : Stock Futures Rise as Jobs Report Swings Into Focus	23-06-02	DJ
Oncorus to Lay Off Almost Entire Workforce -- Shares Slump After-Hours	23-06-01	MT
Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	23-06-01	DJ
Oncorus, Inc. Announces Workforce Reduction Plan	23-06-01	CI
Theodore Ashburn, Chief Executive Officer Departs from the Oncorus, Inc, Effective to Be No Later Than June 30, 2023	23-06-01	CI
Oncorus, Inc. Announces Management Changes, Effective to Be No Later Than June 30, 2023	23-06-01	CI
Oncorus, Inc. Contemplates Bankruptcy	23-06-01	CI
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI

Chart Oncorus, Inc.

Duration

Period

More charts

Company Profile

Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs